Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

David Levitz, Kateryna Fedorov, Kith Pradhan, Lauren C Shapiro, Aditi Shastri, Kira Gritsman, Nishi Shah, Noah Kornblum, R. Alejandro Sica, Ira Braunschweig, Marina Konopleva, Eric J. Feldman, Amit Verma, Ioannis Mantzaris, Yogenthiran Saunthararajah, Mendel Goldfinger

Blood (2022) 140 (Supplement 1): 6218–6219.

https://doi.org/10.1182/blood-2022-170059

Published: 2022

Journal Articles

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Blood (2022) 140 (Supplement 1): 10949–10950.

https://doi.org/10.1182/blood-2022-164841

Published: 2022

Journal Articles

Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid Malignancies

Lauren C Shapiro, Ioannis Mantzaris, Aditi Shastri, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Noah Kornblum, Kira Gritsman, Eric J. Feldman, Amit Verma, Ira Braunschweig, Yogenthiran Saunthararajah, Mendel Goldfinger

Blood (2021) 138 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2021-145960

Published: 2021

Journal Articles

Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort

Blood (2021) 138 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2021-151309

Published: 2021

Journal Articles

A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML

Bianca L Rivera, Shanisha Gordon, Srinivas Aluri, Yang Shi, Samarpana Chakraborty, Gaurav S Choudhary, Lauren C Shapiro, Kith Pradhan, David A. Frank, Sergei B. Koralov, Amit Verma, Aditi Shastri

Blood (2021) 138 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2021-151691

Published: 2021

Journal Articles

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Angelica D'Aiello, Sumaira Zareef, MD, Kith Pradhan, PhD, Amanda Lombardo, PA-C, BS, MS, Fariha Khatun, PA-C, Jennat Mustafa, PA-C, Alyssa De Castro, PharmD, Felisha Joseph, PA-C, Kailyn Gillick, PA-C, Anjali Naik, PA-C, Astha Thakkar, MBBS, Lauren C Shapiro, MD, Shafia Rahman, MD, Zhu Cui, MD, Jesus D Gonzalez Lugo, MD, Fiona Mienko, MBBS, Numa Tarnima Rahman, MD, Robert Lopez, MD, Heidi Chwan Ko, DO, Amanda Podolski, MD, Vikas Mehta, MD, Sanjay Goel, MD, Rafi Kabarriti, MD, Joseph Sparano, MD, Stuart Packer, MD, David Lawrence Fernandes, MD, Enrico Castelucci, MD, Margarita Kushnir, MD, Mark Chaitowitz, MD, Luca Paoluzzi, MD, Ulrich G. Steidl, MDPhD, Phaedon Zavras, MD, Ioannis Mantzaris, MD MS, Noah Kornblum, MD, Aditi Shastri, MD, Lizamarie Bachier-Rodriguez, MD, Kira Gritsman, MDPhD, Henny H. Billett, MD MSc, Rachel Bartash, MD, Yoram Puius, MD PhD, Margaret Mccort, MD, Ira Braunschweig, MD, Mendel Goldfinger, MD, Amit Verma, MBBS, R. Alejandro Sica, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138842

Published: 2020

NARROW

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid Malignancies

Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort

A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Email alerts

ASH Publications

American Society of Hematology

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid Malignancies

Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort

A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only